This study indicated that epileptogenicity in malignant glioma requires the co-existence and reciprocal expression of CD44 and xCT, so both could be potential targets for anti-epileptic and anti-tumoral therapies in GBM. The gene discussed is CD44; the disease is malignant glioma.